Answers are grounded in this paper and cite their sources.
CLB/LN pathology is the most significant correlate of dementia in PD. Additionally, APOE4 genotype may independently influence the risk of dementia in PD. AD pathology was abundant in a subset of patients, and may modify the clinical phenotype. Thus, therapies that target α-synuclein, tau, or amyloid β could potentially improve cognitive performance in PD.
No takes yet. Share an insight, caveat, or question.
Irwin et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: